Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topotecan via CED in High Grade Glioma
NCT02500459Phase 1Terminated
- Start
- Jul 2015
- Primary completion
- Nov 2018
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, open-label trial of topotecan liposome in high-grade glioma (HGG). Primary endpoint: Number of adverse events by grade at 1 year. Started Jul 2015; status: terminated.
02
Drugs
topotecan liposome
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT02500459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02500459.